Zhen Su

As CEO of Marengo Therapeutics and a director of the company’s board, Zhen Su brings more than two decades of experiences as a physician-scientist and business executive, with expertise in building and leading both R&D and commercial organizations. Prior to joining Marengo, Zhen served as Senior Vice President and Global Head of Oncology for Merck KGaA, where he led the franchise’s turnaround to achieve double-digit organic growth and an annual revenue above €1B. In this role, he also successfully expanded the oncology portfolio including key alliance partnerships with Pfizer ($2.8B), GSK ($4.2B), and Debiopharm ($1.1B). In his earlier role as Chief Medical Officer of EMD Serono and head of its Oncology Medical division, he played an instrumental role in 8 major regulatory approvals across different indications for Bavencio®, Tepmetko®, Erbitux®, and Mavenclad®. He also held leadership roles with increasing responsibilities at Sanofi Oncology and GSK. Before his industry career, Zhen served on the faculty of Duke University, where he led early clinical studies focusing on mRNA-based and cell-based immunotherapy, and then the University of Florida, where he was the director of the Cell and Gene Therapy program. He is the author of more than 60 publications in immuno-oncology and targeted oncology.

Zhen earned his M.D. from the Technical University of Dresden, completed his post-doctoral training in tumor immunology at Duke University, and received an MBA from the University of Toronto.